SCHEMBL10079948

SCHEMBL10079948

CC(C)(C)Nc1ccc(C(=O)C(C)(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
MLYCD O95822 3/20 0.40
LMNA P02545 1/20 0.39
PGR P06401 1/20 0.38
AR P10275 1/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
MAPT P10636 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MITF O75030 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
EPHX2 P34913 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17735576 0.89 NPC1 (0.53) MLYCDLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL7901436 0.83 ALDH1A1 (0.47) L3MBTL1LMNAMEN1KMT2AMAPT
SCHEMBL29196079 0.83 MAPK13 (0.47) L3MBTL1MLYCDLMNAPGRAR
SCHEMBL23682711 0.82 MEN1 (0.39) L3MBTL1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL10031827 0.82 PGR (0.47) L3MBTL1MLYCDLMNAPGRAR
SCHEMBL1711131 0.81 EPHX2 (0.55) MEN1KMT2AMAPTSMN1; SMN2MITF
SCHEMBL8284442 0.81 L3MBTL1 (0.45) L3MBTL1MLYCDLMNAPGRAR
SCHEMBL12883549 0.81 MAPT (0.50) L3MBTL1LMNAMEN1KMT2AMAPT
SCHEMBL23239821 0.81 KMT2A (0.57) LMNAMEN1KMT2AMAPTHPGD
SCHEMBL10001145 0.79 L3MBTL1 (0.43) L3MBTL1MLYCDLMNAPGRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 US disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 US disclosed
US-20230144203-A1 DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2023-05-11 US disclosed
US-11209362-B2 Fluorescent probe for detecting sulfenylated protein, preparation method thereof, and application thereof CHONGQING MEDICAL UNIVERSITY (CN) 2021-12-28 US disclosed
US-20210238226-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2021-08-05 US disclosed
US-20210228723-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2021-07-29 US disclosed
US-10919938-B2 Modified cyclopentapeptides and uses thereof Technische Universität München (DE) 2021-02-16 US disclosed
EP-3763766-A1 LIQUID-CRYSTAL POLYMER, LAMINATED MATERIAL, LIQUID-CRYSTAL POLYMER SOLUTION, AND METHOD OF FORMING LIQUID-CRYSTAL POLYMER FILM Industrial Technology Research Institute (TW) 2021-01-13 EP disclosed
US-20200323814-A1 MEDICAL COMPOUND VERA SALUS RICERCA S.R.L. (IT) 2020-10-15 US disclosed
US-9896668-B2 Substrate-mimetic AKT inhibitor UNIVERSITY OF SOUTH FLORIDA (US) 2018-02-20 US disclosed
US-20100145036-A1 CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF MEDAREX, INC. (US) 2010-06-10 US disclosed
US-20100143368-A1 Human Antibodies That Bind Cd22 And Uses Thereof E. R. SQUIBB & SONS, L.L.C. 2010-06-10 US disclosed
US-20100113476-A1 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF E. R. SQUIBB & SONS, L.L.C. 2010-05-06 US disclosed
US-20100104509-A1 HUMAN ANTIBODIES THAT BIND CD19 AND USES THEREOF MEDAREX, INC. (US) 2010-04-29 US disclosed
US-20100092496-A1 CHEMICAL LINKERS AND CONJUGATES THEREOF MEDAREX, INC. (US) 2010-04-15 US disclosed
US-20100093973-A1 POLY(AMINO ACID) COMPOUND HAVING INHIBITORY ACTIVITY ON ABSORPTION OF PHOSPHORUS AND PHOSPHORUS ABSORPTION INHIBITOR AJINOMOTO CO., INC. (JP) 2010-04-15 US disclosed
US-7691962-B2 Chemical linkers and conjugates thereof MEDAREX, INC. (US) 2010-04-06 US disclosed
US-20090162372-A1 FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE MEDAREX, INC. (US) 2009-06-25 US disclosed
US-20080279868-A1 Antibody-Drug Conjugates and Methods of Use MEDAREX, INC. (US) 2008-11-13 US disclosed
US-7166695-B2 Affinity markers for human serum albumin CONJUCHEM BIOTECHNOLOGIES INC. (CA) 2007-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162372-A1 FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE FN1, EDNRB, EDF1 L3MBTL1 1918/4885MLYCD 4058/4885LMNA 1466/4885
US-20210238226-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE ATXN2L, ATXN2, ATXN10 L3MBTL1 3195/4885MLYCD 3433/4885LMNA 1046/4885
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE DMPK, DTYMK, MYCBP L3MBTL1 429/4885MLYCD 1934/4885LMNA 136/4885
US-20100093973-A1 POLY(AMINO ACID) COMPOUND HAVING INHIBITORY ACTIVITY ON ABSORPTION OF PHOSPHORUS AND PHOSPHORUS ABSORPTION INHIBITOR ALPI, SLC7A1, SLC34A1 L3MBTL1 4197/4885MLYCD 4281/4885LMNA 3506/4885
US-20100113476-A1 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF DNPEP, ANTXR2, CLSPN L3MBTL1 255/4885MLYCD 2256/4885LMNA 3365/4885
US-20100143368-A1 Human Antibodies That Bind Cd22 And Uses Thereof CD2BP2, CD22, CD2 L3MBTL1 823/4885MLYCD 4562/4885LMNA 4068/4885
US-20200323814-A1 MEDICAL COMPOUND MTNR1B, CBR1, MTNR1A L3MBTL1 2406/4885MLYCD 3351/4885LMNA 4697/4885
US-20080279868-A1 Antibody-Drug Conjugates and Methods of Use CD47, ANTXR2, CD2BP2 L3MBTL1 1076/4885MLYCD 3306/4885LMNA 2347/4885
US-20210228723-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE ZFX, F13B, GRN L3MBTL1 718/4885MLYCD 2641/4885LMNA 188/4885
US-20100104509-A1 HUMAN ANTIBODIES THAT BIND CD19 AND USES THEREOF BCL9, BCL9L, BCL6B L3MBTL1 258/4885MLYCD 3633/4885LMNA 1383/4885
US-20100092496-A1 CHEMICAL LINKERS AND CONJUGATES THEREOF CLSPN, CD74, ANTXR2 L3MBTL1 900/4885MLYCD 3129/4885LMNA 3757/4885
US-20230144203-A1 DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE ERLIN1, ERLIN2, EZR L3MBTL1 4224/4885MLYCD 1652/4885LMNA 3528/4885
US-10919938-B2 Modified cyclopentapeptides and uses thereof ANXA4, CPA4, PTMS L3MBTL1 435/4885MLYCD 3313/4885LMNA 1683/4885
US-11209362-B2 Fluorescent probe for detecting sulfenylated protein, preparation method thereof, and application thereof TST, SUMO1, SUMO3 L3MBTL1 2662/4885MLYCD 3027/4885LMNA 1934/4885
US-20100145036-A1 CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF XIAP, ADAM8, CLSPN L3MBTL1 522/4885MLYCD 1583/4885LMNA 1546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.